Blog | HemaCare

PBMCs and Psoriasis Treatments

Jun 18, 2018 10:11:00 AM / by Stacy Matthews Branch, DVM, PhD

Psoriasis patientScientists examined the peripheral blood mononuclear cell (PBMC) profiles of patients with and without psoriasis, including those that both responded to classic treatments and didn’t respond. They then analyzed the profile of those immune cell types. Here are the results of that study.

There are often differences among patient populations for a given disease in how effective a treatment provides medical relief. An important part of personalized medicine is identifying patients that are not likely to respond to a treatment regimen for a specific disease or condition. Doing this can limit the loss of time and resources in using ineffective treatments and can allow the use of personalized treatments in these populations.

Moderate to severe psoriasis does not respond well to topical treatment, and many with this condition also do not respond to systemic treatments. A group of scientists examined the peripheral blood mononuclear cell (PBMC) profiles of patients with and without psoriasis and those that responded (or not) to classic treatments. PBMCs were collected from patients initially taking systemic drugs for psoriasis and healthy controls. The cells were then sorted and the profile of immune cell types was analyzed.

After analysis, the researchers had some interesting observations. For instance, there were higher levels of monocytes and lower levels of helper and cytotoxic T cells in the PBMCs from patients with psoriasis compared to those from healthy controls. However, these differences were not seen when treatment responders and non-responders were compared. Instead, the PBMCs from non-responders was higher in B cells when compared to those of responders or healthy controls.

Looking at cytokines produced from PBMC cells provided further insight. In the case of TNF-alpha and IFN-gamma, the level of monocytes producing these cytokines was higher in patients with psoriasis when compared to healthy controls, but the level of cytotoxic T cells producing these were lower. The level of T helper cells that produced IFN-gamma was lower in non-responders; however, there were no differences in the production of cytokines in B cells between responders and non-responders. Overall, those patients with high levels of B cells and low levels of T helper cells producing IFN-gamma may be biomarkers that can identify patients who are not likely to respond to classic treatments and who may instead need alternative therapeutic approaches.  

For PBMCs and other cells to support your research, see HemaCare’s supply of ready-to-ship cells and tissues.



Sunali Wadehra, M. (2018). Differentiating Responders to Systemic Therapies from Nonresponders With Psoriasis. Retrieved 10 May 2018, from

Topics: B Cells, PBMCs, Helper T Cells, immune cells

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts